IDH2 and neoplasm: For example, the metabolic product of mutant IDH1/2, 2-hydroxiglutarate (2-HG), suppresses antitumor activity of tumor-infiltrated cytotoxic T-cells in vivo [94], and therefore, IDH mutations are, per se, targets for new vaccines.